, American college of phlebology, society for
vascular medicine, and international union of phlebology. J Vasc
Surg Venous Lymphat Disord 2019;7:17-28.
101. Mansilha A, Sousa J. Pathophysiological mechanisms of chronic
venous disease and implications for venoactive drug therapy. Int J
Mol Sci 2018;19.
102. Gloviczki M. Micronized Puriﬁed Flavonoid Fraction (MPFF) for
Chronic Venous and Lymphatic Disorders 2021. Vein Therapy News.
Available at: https://digitaleditions.walsworth.com/publication/?i¼7
03330&article_id¼3999246&view¼articleBrowser.
Accessed
October 19, 2023.
103. Bush R, Comerota A, Meissner M, Raffetto JD, Hahn SR, Freeman K.
Recommendations for the medical management of chronic
venous disease: the role of Micronized Puriﬁed Flavanoid Fraction
(MPFF). Phlebology 2017;32(1_suppl):3-19.
104. Martinez-Zapata MJ, Vernooij RW, Uriona Tuma SM, et al. Phlebotonics for venous insufﬁciency. Cochrane Database Syst Rev 2016;4:
CD003229.
105. Martinez-Zapata MJ, Vernooij RW, Simancas-Racines D, et al. Phlebotonics for venous insufﬁciency. Cochrane Database Syst Rev
2020;11:Cd003229.
106. Ibegbuna V, Nicolaides AN, Sowade O, Leon M, Geroulakos G.
Venous elasticity after treatment with Daﬂon 500 mg. Angiology
1997;48:45-9.
107. Krzysciak W, Cierniak A, Kozka M, Koziel J. Oxidative DNA damage
in blood